soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π The SOUL trial (Semaglutide Cardiovascular
Description
Reconstituting the drug in this manner creates a liquid solution, purportedly the equivalent of the brand-name drug, which can then be injected under the skin
[DOI] [PubMed] [Google Scholar] 80.Parkman HP, Harris AD, Miller MA, et al
-$2M(-2M) Debt/Value 4 Includes stadium debt and is based on May 14
In this episode of CardioNerds co-founder Dr
Areas we serve
